Released Nov 9, 2016, after the close
10-Q filed Nov 9, 2016, 40 days after period end · 0001390478-16-000164
Q3 2016 · 10-Q
Revenue—
Net Income-$6.93M-$6.93M no prior Q3 2015 on fileN/M vs Q2 2016
EPS, diluted—
Operating Income-$6,472,000—
Operating Cash Flowderived-$12,208,000—
Free Cash Flowderived-$12,208,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2016 | Q3 2013 | Q3 2012 | Q3 2011 |
|---|---|---|---|---|
| Revenue | — | $2.17M | $2.17M | — |
| Net Income | -$6.93M | -$6.93M | -$18.03M | -$5.48M |
| EPS Diluted | — | -$0.11 | -$0.09 | -$0.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR